Body Weight is Inversely Associated with Anti-SARS-CoV-2 Antibody Levels after BNT162b2 mRNA Vaccination in Young and Middle Aged Adults
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: This study aimed to determine factors affecting serum levels of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies 2 months after coronavirus disease 2019 (COVID-19) vaccination in young and middle aged healthy adults. Materials and methods: Healthcare workers who have no history of SARS-CoV-2 infection, were enrolled at 2 months after second shot of BNT162b2 mRNA COVID-19 vaccine. Antibody immunoglobulin G against the spike protein subunit of SARS-CoV-2 was semi-quantitatively measured using 4 commercial enzyme-linked immunosorbent assay kits. Factors affecting anti-SARS-CoV-2 antibodies levels were investigated. Results: Fifty-one persons (22 - 54 years, male sex; 19.6%) were enrolled and all participants acquired anti-SARS-CoV-2 antibodies in four diagnostic kits. Anti-SARS-CoV-2 antibodies were strongly correlated between diagnostic kits; SG Medical and Genscript (r = 0.942), SG Medical and HB Healthcare (r = 0.903), and HB Healthcare and Genscript (r = 0.868). We investigated factors affecting antibody level using SG medical kit. The median inhibition was 93.1%, and 84.0% of participants showed >90.0% inhibition. Systemic adverse event severity had no association with the anti-SARS-CoV-2 antibodies level. Antibody level was inversely correlated with weight (-0.312, P = 0.027), body mass index (BMI) (r = -0.303, P = 0.032), and body surface area (r = -0.285, P = 0.044). In multivariate analysis, the upper 50% of anti-SARS-CoV-2 antibodies (≥93.1%) was inversely associated with weight (odds ratio [OR]: 0.19; 95% confidence interval [CI]: 0.04 - 0.83 in weight ≥55kg) and BMI (OR: 0.12; 95% CI: 0.03 - 0.61 in BMI ≥22 kg/m²). Conclusion: Anti-SARS-CoV-2 antibody was inversely correlated with weight and BMI, which may be used as a marker to predict immune response of BNT162b2 mRNA vaccination in young and middle aged adults. Trial registration: ClinicalTrials.gov Identifier: NCT05083026.
Abstract
Background: This study aimed to determine factors affecting serum levels of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies 2 months after coronavirus disease 2019 (COVID-19) vaccination in young and middle aged healthy adults. Materials and methods: Healthcare workers who have no history of SARS-CoV-2 infection, were enrolled at 2 months after second shot of BNT162b2 mRNA COVID-19 vaccine. Antibody immunoglobulin G against the spike protein subunit of SARS-CoV-2 was semi-quantitatively measured using 4 commercial enzyme-linked immunosorbent assay kits. Factors affecting anti-SARS-CoV-2 antibodies levels were investigated. Results: Fifty-one persons (22 - 54 years, male sex; 19.6%) were enrolled and all participants acquired anti-SARS-CoV-2 antibodies in four diagnostic kits. Anti-SARS-CoV-2 antibodies were strongly correlated between diagnostic kits; SG Medical and Genscript (r = 0.942), SG Medical and HB Healthcare (r = 0.903), and HB Healthcare and Genscript (r = 0.868). We investigated factors affecting antibody level using SG medical kit. The median inhibition was 93.1%, and 84.0% of participants showed >90.0% inhibition. Systemic adverse event severity had no association with the anti-SARS-CoV-2 antibodies level. Antibody level was inversely correlated with weight (-0.312, P = 0.027), body mass index (BMI) (r = -0.303, P = 0.032), and body surface area (r = -0.285, P = 0.044). In multivariate analysis, the upper 50% of anti-SARS-CoV-2 antibodies (≥93.1%) was inversely associated with weight (odds ratio [OR]: 0.19; 95% confidence interval [CI]: 0.04 - 0.83 in weight ≥55kg) and BMI (OR: 0.12; 95% CI: 0.03 - 0.61 in BMI ≥22 kg/m²). Conclusion: Anti-SARS-CoV-2 antibody was inversely correlated with weight and BMI, which may be used as a marker to predict immune response of BNT162b2 mRNA vaccination in young and middle aged adults. Trial registration: ClinicalTrials.gov Identifier: NCT05083026.
참고문헌 (21)
- Lan J, "Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor", Nature, 581, pp.215~220 (2020)
- Krammer F, "SARS-CoV-2 vaccines in development", Nature, 586, pp.516~527 (2020)
- Walsh EE, "Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates", N Engl J Med, 383, pp.2439~2450 (2020)
- Folegatti PM, "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 : a preliminary report of a phase 1", 2, single-blind, randomised controlled trial, 2020, pp.396, 467~478
- Polack FP, "Safety and efficacy of the BNT162b2 mRNA Covid-19vaccine", N Engl J Med, 383, pp.2603~2615 (2020)
- Ramasamy MN, "Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults(COV002) : a single-blind, randomised, controlled, phase 2", 3 trial, 2021, pp.396, 1979~1993
- Khoury DS, "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection", Nat Med, 27, pp.1205~1211 (2021)
- Jackson LA, "An mRNA vaccine against SARS-CoV-2-preliminary report", N Engl J Med, 383, pp.1920~1931 (2020)
- Keech C, "Phase 1-2trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine", N Engl J Med, 383, pp.2320~2332 (2020)
- Nam SY, "Demographic and clinical factors associated with anti-SARS-CoV-2 antibody levels after 2 BNT162b2 mRNA vaccine doses", JAMA Netw Open, 5, pp.e2212996~ (2022)
- Young Hoon Hwang, "Can reactogenicity predict immunogenicity after COVID-19 vaccination?", The Korean Journal of Internal Medicine, 36(6), pp.1486~1491 (2021), 대한내과학회[DOI]
- Maeda K, "Correlates of neutralizing", SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals, 2021
- Kwon Hyun Hee, "Healthcare Workforce Response to The Coronavirus Disease Outbreak in Daegu, Korea: A Multi-Center, Cross-Sectional Survey", Infection and Chemotherapy, 54(2), pp.298~307 (2022), 대한감염학회[DOI]
- Mosteller RD, "Simplified calculation of body-surface area", N Engl J Med, 317, pp.1098~ (1987)
- Yamamoto S, "Sex-associated differences between BMI and SARS-CoV-2 antibody titers following the BNT162b2 vaccine", Obesity(Silver Spring), 30, pp.999~1003 (2022)
- Piernas C, "Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England : a population-based cohort study", Lancet Diabetes Endocrinol, 10, pp.571~580 (2022)
- Sanghavi DK, "Low antispike antibody levels correlate with poor outcomes in COVID-19 breakthrough hospitalizations", J Intern Med, 292, pp.127~135 (2022)
- Soffer S, "The association between obesity and peak antibody titer response in COVID-19 infection", Obesity(Silver Spring), 29, pp.1547~1553 (2021)
- Mulligan MJ, "Phase I", II study of COVID-19RNA vaccine BNT162b1 in adults, 2020, pp.586, 589~593
- Hervé C, "The how’s and what’s of vaccine reactogenicity", NPJ Vaccines, 4, pp.39~ (2019)
- Goel RR, "mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern", Science, 374, pp.abm0829~ (2021)